Form 4: Spyre Therapeutics CFO Granted 140,000 Stock Options

Spyre Therapeutics' CFO, Scott L. Burrows, was granted 140,000 stock options with an exercise price of $30.61, vesting over four years.

Summary

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), reported the acquisition of derivative securities.
• The transaction involved a stock option (right to buy) for 140,000 shares of the Issuer's common stock.
• The exercise price for these options is $30.61 per share.
• The options were granted on January 9, 2026, and become exercisable on the same date.
• The options will vest in equal monthly installments over a four-year period, contingent on Mr. Burrows' continued employment.
• The expiration date for these stock options is January 9, 2036.
• Following this transaction, Mr. Burrows beneficially owns 140,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant), which is generally a neutral to slightly positive signal as it aligns management incentives with shareholder interests. It does not contain information that would significantly alter the company's immediate outlook.

Positives

• The grant of 140,000 stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedule over four years encourages sustained commitment and performance from a key executive.

Future Outlook

The stock options granted to the CFO are subject to a four-year vesting schedule, contingent on continued employment, indicating a long-term commitment from the executive to the company's future performance.

Industry Context

The grant of stock options to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of executive compensation to attract, retain, and motivate key talent by linking their financial incentives to the company's stock performance.

Stakeholder Impact

• Shareholders: The grant of stock options to the CFO aligns his financial interests with those of shareholders, potentially leading to more focused efforts on increasing shareholder value.
• Employees: This compensation structure may serve as a benchmark or incentive for other key employees, influencing overall compensation strategies.

Next Steps

• Continued employment of Scott L. Burrows with Spyre Therapeutics for the options to vest according to the four-year schedule.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Stock Options, CFO, Executive Compensation, Insider Transaction, Form 4, Equity Grant